Russian Heart Failure Journal 2010year Clinical, laboratory and instrumental diagnostic markers of CHF


To access this material please log in or register

Register Authorize
2010/

Clinical, laboratory and instrumental diagnostic markers of CHF

Kosarev M. M., Obrezan A. G., Strelnikov A. A.

Keywords: chronic heart failure, tissue Doppler Echocardiography, time velocity integral (TVI), brain natriuretic peptide (BNP), early stages of CHF development

DOI: 10.18087/ rhfj.2010.3.1315

CHF manifestation is characterised by several low-sensitivity and low-specific signs and symptoms, forming clinical syndromes of CHF. Experts from ESC and ACC / AHA analysed clinical, laboratory and instrumental signs of CHF, and recommend to use a number of clinical and laboratory methods for the most early diagnosis. Measurement of brain natriuretic peptide (BNP) and / or N-terminal brain natriuretic propeptide (NT-proBNP) levels, as well as tissue Doppler echocardiography (TVI) allows to detect CHF on early stages of CHF development. The level of BNP and / or NT-proBNP is highly specific and highly sensitive indicators of LV overload. In turn, measurment of local contractility in TVI mode allows to detect CHF on asymptomatic stage of development. TVI Q-mode asseses not only global, but also local myocardial contractility and relaxation, and provides more precise objective and quantitative evaluation of these parameters. Many cohort studies confirm the high specificity and sensitivity of BNP, NT-proBNP level and TVI analysis on early stages of CHF.
  1. Обрезан А. Г., Вологдина И. В. Хроническая сердечная недостаточность. –С-Пб: "Вита Нова". – 2002. – 320 с.
  2. Jessup M, Abraham WT, Casey DE et al. 2009 focused update: ACCF / AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119 (14):1977–2016.
  3. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29 (19):2388–2442.
  4. Mant J, Doust J, Roalfe A et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess. 2009;13 (32):1–207.
  5. Мошина В. А., Верткин А. Л., Сапрыгин Д. Б. Роль мозгового натрий уретического пептида в стратификации риска у больных с острым коронарным синдромом без подьема ST. Лабораторная медицина. 2005;7:95–102.
  6. Напалков Д. А., Сеидова Н. М., Сулимов В. А. Хроническая сердечная недостаточность: смещение фокуса на начальные стадии заболевания. Лечащий врач. 2008;4:58–60.
  7. Cohen-Solal A, Logeart D, Huang B et al. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol. 2009;53 (25):2349–2352.
  8. Norman JF, Pozehl BJ, Duncan KA et al. Relationship of Resting B-type Natriuretic Peptide Level to Cardiac Work and Total Physical Work Capacity in Heart Failure Patients. J Cardiopulm Rehabil Prev. 2009;29 (5):310–313.
  9. Mueller C, Scholer A, Laule-Kilian K et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350 (7):647–654.
  10. Newton PJ, Betihavas V, Macdonald P. The role of b-type natriuretic peptide in heart failure management. Aust Crit Care. 2009;22 (3):117–123.
  11. Greenberg B. Can we IMPROVE-CHF management by measuring natriuretic peptides? Circulation. 2007;115 (24):3045–30457.
  12. Moe GW, Howlett J, Januzzi JL, Zowall H. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation. 2007;115 (24):3103–3110.
  13. Boldanova T, Noveanu M, Breidthardt T et al. Impact of history of heart failure on diagnostic and prognostic value of BNP: Results from the B-type Natriuretic Peptide for Acute Shortness of Breath Evaluation (BASEL) Study. Int J Cardiol. 2009 Jan 28. [Epub ahead of print]
  14. Morrison LK, Harrison A, Krishnaswamy P et al. Utility of a rapid B-natri­uretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002;39 (2):202–209.
  15. Magnusson M, Jovinge S, Rydberg E et al. Natriuretic peptides as indicators of cardiac remodeling in hypertensive patients. Blood Press. 2009 Jun 26:1–8.
  16. Rasmus Mogelvang, Peter Sogaard, Sune A. Pedersen et al. Tissue Doppler echocardiography in persons with hypertension, diabetes, or ischaemic heart disease: the Сopenhagen City Heart Study European Heart Journal. 2009;30:731–739.
  17. Andersen NH, Poulsen SH. Evaluation of the longitudinal contraction of the left ventricle in normal subjects by Doppler tissue tracking and strain rate. J Am Soc Echocardiogr. 2003;16 (7):716–723.
  18. Pan C, Hoffmann R, Kuhl H et al. Tissue tracking allows rapid and accurate visual evaluation of left ventricular function. Eur J Echocardiogr. 2001;2 (3):197–202.
  19. Sogaard P, Egeblad H, Kim WY et al. Tissue doppler imaging predicts improved systolic performance and reversed left ventricular remodeling during long-term cardiac resynchronization therapy. J Am Coll Cardiol. 2002;40 (4):723–730.
  20. Waggoner AD, Bierig SM. Tissue Doppler imaging: a useful echocardiographic method for the cardiac sonographer to assess systolic and diastolic ventricular function. J Am Soc Echocardiogr. 2001;14 (12):1143–1152.
  21. Sadeghian H, Majidi S, Lotfi-Tokaldany M et al. Evaluation of longitudinal tissue velocity and deformation imaging in akinetic nonviable inferobasal segments of left ventricular myocardium by dobutamine stress echocardiography. Echocardiography. 2009;26 (7):801–806.
  22. Schneider C, Bahlmann E, Malisius R et al. Tissue velocity imaging during dobutamine stimulation for assessment of myocardial viability: segmental analysis in patients after myocardial infarction. Int J Cardiol. 2006;110 (1):15–21.
  23. Bjallmark A, Larsson M, Shahgaldi K et al. Differences in myocardial velocities during supine and upright exercise stress echocardiography in healthy adults. Clin Physiol Funct Imaging. 2009;29 (3):216–223.
  24. Bayrak, Fatih, Kahveci et al. Tissue Doppler imaging to predict clinical course of patients with hypertrophic cardiomyopathy. Eur J Echocardiogr. 2008;9 (2):278–283.
  25. Bellavia D, Pellikka PA, Abraham TP et al. Hypersynchronisation by tissue velocity imaging in patients with cardiac amyloidosis. Heart. 2009;95 (3):234–240.
  26. Betti I, Castelli G, Barchielli A et al. The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study. J Card Fail. 2009;15 (5):377–384.
  27. Оганов Р. Г., Мамедов М. Н. Национальные клинические рекомендации ВНОК. – М.: «Силицея-Полиграф», 2008. – 512с.
Kosarev M. M., Obrezan A. G., Strelnikov A. A. Clinical, laboratory and instrumental diagnostic markers of CHF. Russian Heart Failure Journal. 2010;11(3):177-184.

To access this material please log in or register

Register Authorize
Ru En